Data presented in this case report provides an important platform to explore combination therapy based on anti-PD-1 and anti-EBV T cell therapy to further improve the overall survival of NPC patients with recurrent metastatic disease. This evidence concerns the gene PDCD1 and nasopharyngeal carcinoma.